Study shows benefits of DePuy hip implants
New clinical results from orthopaedics device company DePuy Synthes show that its Corail Hip System Femoral Stems are associated with a lower revision risk compared to similar available devices.
Results announced at the 2nd World Arthroplasty Congress reveal a 29% lower revision risk when compared to all other cementless stems on the National Joint Registry (NJR) for England, Wales, Northern Ireland and the Isle of Man.
Speaking about the results Torbjorn Sköld, Vvice president, DePuy Synthes EMEA Joint Reconstruction, said: “While the entire Corail portfolio has a long and successful clinical heritage, this latest information is significant as it reinforces that using a proven, robust construct design with a strong supportive evidence base may help reduce the revision risk for patients and the associated cost burden to healthcare systems.”
DePuy Synthes commissioned the analysis to provide the orthopaedic community with new outcomes data on one of its most widely used implants. The analysis compared the survivorship rates of the Corail Standard Collared and Collarless Femoral Stems to all other cementless femoral stems in the NJR.
You can read the full analysis here.